A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)

British Journal of Clinical Pharmacology

Volumn 56, Issue 1, 2003, Pages 46-56

  Callies, Sophie ^b   De Alwis, Dinesh P ^a   Harris, Adrian ^d   Vasey, Paul ^e   Beijnen, Jos H ^c   Schellens, Jan H ^c   Burgess, Michael ^a   Aarons, Leon ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

P glycoprotein modulator; Paclitaxel; Population pharmacokinetics; Zosuquidar 3HCl

Indexed keywords

CREMOPHOR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; PACLITAXEL; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ZOSUQUIDAR;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INFUSION; DRUG SAFETY; FEMALE; HUMAN; IC 50; INTRAHEPATIC BILE DUCT; MALE; PHARMACOKINETICS; PLASMA CLEARANCE; POPULATION MODEL; POPULATION PHARMACOKINETICS; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COHORT STUDIES; DIBENZOCYCLOHEPTENES; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; QUINOLINES;

EID: 0038675082     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01826.x     Document Type: Article

References (38)

1. Grochow LB, Ames MM. A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics, 1st edn. Baltimore, Williams & Wilkins Publishers, 1998; 93-122.
2. Walle T, Walle UK, Kumar GN, Bhalla KN. Taxol metaoblism and disposition in cancer patients. Drug Metab Dispos 1995; 23: 506-512.
3. Pivot X, Asmar L, Hortobagyi GN. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer. Int J Oncol 1999; 15: 381-386.
4. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J Clin Oncol 1999; 17: 1061-1070.
5. Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH. Extensive contribution of the multidrug transporters P-glycoprotein and MRP1 to basal drug resistance. Cancer Res 2000; 60: 5761-5766.
6. Sekine I, Saijo N. Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann Oncol 2001; 12: 1515-1525.
7. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer; mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11: 265-283.
8. Advani R, Fisher GA, Lum BL, et al. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC833), a modulator of multidrug resistance. Clin Cancer Res 2001; 7: 1221-1229.
9. Chico I, Kang MH, Bergan R, et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC833. J Clin Oncol 2001; 19: 832-842.
10. Giaccome G, Linn SC, Welink J, et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 1997; 3: 2005-2015.
11. Sparreboom A, Planting AST, Jewell RC, et al. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anti-Cancer Drugs 1999; 10: 719-728.
12. Ferry D, Price L, Atsmon J, et al. A phase HA pharmacokinetic and pharmacodynamic study of the P-glycoprotein inhibitor, XR9576, in patient treated with doxorubicin chemotherapy. Proc AACR 2001; 42: 950-5160.
13. Peck RA, Hewett J, Harding MW, et al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 2001; 19: 3130-3141.
14. Rowinsky EK, Smith L, Wang YM, et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by over expression of both MDR and MRP. J Clin Oncol 1998; 16: 2964-2976.
15. De Alwis DP, Pouliquen I, Burgess M, et al. A phase I dose escalating study of LY335979, a novel Pgp modulator - administered intravenously in combination with doxorubicin. Proceedings ASCO 2001; 20 (part 1): 284-272a.
16. Dantzig AH, Law KL, Cao J, et al. Reversal of multidrug resistance by the P-glycoprotein modulator LY335979, from the bench to the clinic. Curr Med Chem 2001; 8: 39-50.
17. Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996; 56: 4171-4179.
18. Dantzig AH, Shepard RL, Law KL, et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 1999; 290: 854-862.
19. Green LJ, Marder P, Slapak CA. Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem Pharmacol 2001; 61: 1393-1399.
20. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM Users guide. NONMEM Project Group. San Francisco: University of California, 1994.
21. Kruijtzer CMF, Vasey PA, Harris A, et al. A phase I dose ranging study of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) administered in combination with paclitaxel in patients with solid tumors). Clin Cancer Res, in press.
22. Sparreboom A, de Bruijn P, Nooter K, et al. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1998; 705: 159-164.
23. Scheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000; 40: 67-95.
24. Sun H, Fadiran EO, Jones CD, et al. Population pharmacokinetics - A regulatory perspective. Clin Pharmacokinet 1999; 37: 41-51.
25. Wade JR, Beal SL, Sambol NC. Interaction between structural, statistical and covariates models in population pharmacokinetic analysis. J Pharmacokinet Biopharm 1994; 22: 165-177.
26. Karlsson MO, Sheiner LB. The importance of modeling interoccassion variability in population pharmacokinetic analysis. J Pharmacokinet Biopharm 1993; 21: 735.750.
27. Gianni L, Kearns CM, Gianni A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J Clin Pharmacol 1995; 13: 180-190.
28. Huizing MT, Giaccone G, van Warmerdam LJC, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer: an ECC trial. J Clin Oncol 1997; 15: 317-329.
29. Huizing MT, Keung CF, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11: 2127-2135.
30. Huizing MT, van Warmerdam LJC, Rosing H, et al. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 1997; 15: 1953-1964.
31. Huizing MT, Vermorken JB, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 1995; 6: 699-704.
32. Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37: 1590-1598.
33. Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implication. Cancer Res 1999; 59: 1454-1457.
34. Van Zuylen L, Gianni L, Verweij J, et al. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients. Anti-Cancer Drugs 2000; 11: 331-337.
35. Van Zuylen L, Karlsson MO, Verweij J, et al. Pharmacokinetic modeling of paclitaxel encapulation in cremophor EL micelles. Cancer Chemother Pharmacol 2001; 47: 309-318.
36. Henningson A, Karlsson MO, Vigano L, et al. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 2001; 19: 4065-4073.
37. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic / pharmacodynamic model building aid for NONMEM. Comput Meth Programs Biomed 1999; 58: 51-64.
38. Van der Bongard HJ, Mathot RA, van Telligen O, Schellens JH, Beijnen JH. A population analysis of the pharmacokinetics of cremophor EL using non-linear mixed effect modelling. Cancer Chemother Pharmacol 2002; 50: 16-24.